<DOC>
	<DOCNO>NCT03051009</DOCNO>
	<brief_summary>Demonstrate safety tolerability desmopressin ODT long-term treatment subject nocturia due nocturnal polyuria , 1 year</brief_summary>
	<brief_title>Trial Investigating Long Term Safety Tolerability Desmopressin Orally Disintegrating Tablets ( ODT ) Nocturia Due Nocturnal Polyuria Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Nocturia</mesh_term>
	<mesh_term>Polyuria</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Inclusion Criteria ( subject participate trial 000129 000130 ) : Written inform consent prior performance trialrelated activity 000131 trial Has complete participation trial 000129 000130 Exclusion Criteria ( subject participate trial 000129 000130 ) : Hyponatraemia ( serum sodium level &lt; 135 mmol/L ) Visit 7 trial 000129 000130 Withdrawal clinical trial 000129 000130 Inclusion Criteria ( subject participate trial 000129 000130 ) : Written inform consent prior performance trialrelated activity Adult ≥20 year age Nocturia symptom present ≥6 month prior trial entry Visit 1a Nocturnal polyuria end screen period prior Visit 1b Bothered nocturia Hsu 5point Likert bother scale Visit 1a Visit 1b Has give agreement contraception trial Exclusion Criteria ( subject participate trial 000129 000130 ) : Early withdrawal clinical trial 000129 000130 Evidence significant void dysfunction result abnormally low bladder capacity end screening period prior Visit 1b History evidence significant obstructive sleep apnoea History diagnosis follow urological disease : Interstitial cystitis bladder pain disorder In male , suspicion moderate severe benign prostate hyperplasia ( BPH ) , define international prostate symptom score ( IPSS ) ≥8 point : Urinary flow &lt; 5 mL/s Postvoid residual volume &gt; 150 mL Stress urinary incontinence mixed incontinence , stress incontinence predominant component base prior history Chronic prostatitis/chronic pelvic pain syndrome Surgical treatment , include transurethral resection , BOO BPH within past 6 month prior Visit 1a Symptoms severe overactive bladder ( OAB ) : Defined overactive bladder symptom score ( OABSS ) ≥12 Visit 1a Defined mean &gt; 8 void mean ≥1 urgency episode per 24 hour end screen period prior Visit 1b Genitourinary tract pathology investigator 's opinion responsible urgency urinary incontinence Visit 1a Complication cancer history cancer remission last 5 year Visit 1a Current history urologic malignancy , low urinary tract surgery , previous pelvic irradiation , neoplasia Visit 1a History neurological disease affect bladder function muscle strength Visit 1a Habitual psychogenic polydipsia base medical history Visit 1a 24hour urine output &gt; 2.8 L base void diary Visit 1b Central nephrogenic diabetes insipidus Visit 1a Syndrome inappropriate antidiuretic hormone secretion Visit 1a Suspicion evidence cardiac failure Visit 1a Uncontrolled hypertension Visit 1a Visit 1b Hyponatraemia ( serum sodium level &lt; 135 mmol/L ) Visit 1a Renal insufficiency Visit 1a Visit 1b Renal insufficiency Visit 1a Visit 1b Hepatic and/or biliary disease Visit 1a Visit 1b Known suspect hypersensitivity desmopressin ODTs previous desmopressin treatment nocturia Visit 1a In female , pregnancy , breastfeeding , plan become pregnant period clinical trial . Known alcohol substance abuse Visit 1a Work lifestyle may interfere regular nighttime sleep Visit 1a , e.g. , shift worker Any medical condition , laboratory abnormality , psychiatric condition , mental incapacity , language barrier , judgment investigator , would impair participation trial Visit 1a Use prohibit therapy trial period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>